IL17A and metabolic dysfunction-associated steatohepatitis: Thomas Fabre et al. showed in vitro that IL17A upregulates the HSCs surface expression of TGF-βRII and enhances their response to TGFβ, thus promoting steatohepatitis, indirectly emphasizing the importance of Th17 in NASH progression [74].